These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 30102965)

  • 1. A phase 2a study of toreforant, a histamine H
    Kollmeier AP; Barnathan ES; O'Brien C; Chen B; Xia YK; Zhou B; Loza MJ; Silkoff PE; Ge M; Thurmond RL
    Ann Allergy Asthma Immunol; 2018 Nov; 121(5):568-574. PubMed ID: 30102965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 2a, randomized, double-blind, placebo-controlled, multicentre, parallel-group study of an H
    Kollmeier AP; Greenspan A; Xu XL; Silkoff PE; Barnathan ES; Loza MJ; Jiang J; Zhou B; Chen B; Thurmond RL
    Clin Exp Allergy; 2018 Aug; 48(8):957-969. PubMed ID: 29682796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Toreforant, a Selective Histamine H4 Receptor Antagonist, for the Treatment of Moderate-to-Severe Plaque Psoriasis: Results from a Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Trial.
    Frankel E; Song M; Li S; Jiang J; Thurmond RL; Randazzo B
    J Drugs Dermatol; 2018 Aug; 17(8):873-879. PubMed ID: 30124726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toreforant, A Histamine H4 Receptor Antagonist, in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy: Results of 2 Phase II Studies.
    Thurmond RL; Greenspan A; Radziszewski W; Xu XL; Miao Y; Chen B; Ge T; Zhou B; Baker DG; Pavlova D; Ritchlin CT; Tanaka Y; Takeuchi T; Smolen JS
    J Rheumatol; 2016 Sep; 43(9):1637-42. PubMed ID: 27422891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toreforant, an orally active histamine H
    Boyle DL; DePrimo SE; Calderon C; Chen D; Dunford PJ; Barchuk W; Firestein GS; Thurmond RL
    Inflamm Res; 2019 Apr; 68(4):261-274. PubMed ID: 30739130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study.
    Nathan RA; Rooklin A; Schoaf L; Scott C; Ellsworth A; House K; Dorinsky P
    Clin Ther; 2006 Jan; 28(1):73-85. PubMed ID: 16490581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 12-week, multicenter, randomized, partially blinded, active-controlled, parallel-group study of budesonide inhalation suspension in adolescents and adults with moderate to severe persistent asthma previously receiving inhaled corticosteroids with a metered-dose or dry powder inhaler.
    Murphy K; Noonan M; Silkoff PE; Uryniak T
    Clin Ther; 2007 Jun; 29(6):1013-26. PubMed ID: 17692718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Ferguson GT; FitzGerald JM; Bleecker ER; Laviolette M; Bernstein D; LaForce C; Mansfield L; Barker P; Wu Y; Jison M; Goldman M;
    Lancet Respir Med; 2017 Jul; 5(7):568-576. PubMed ID: 28545978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of AZD7594, an inhaled non-steroidal selective glucocorticoid receptor modulator, in patients with asthma: a phase 2a randomized, double blind, placebo-controlled crossover trial.
    Brown MN; Fuhr R; Beier J; Su HL; Chen Y; Forsman H; Hamrén UW; Jackson H; Aggarwal A
    Respir Res; 2019 Feb; 20(1):37. PubMed ID: 30777086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial.
    Gonem S; Berair R; Singapuri A; Hartley R; Laurencin MFM; Bacher G; Holzhauer B; Bourne M; Mistry V; Pavord ID; Mansur AH; Wardlaw AJ; Siddiqui SH; Kay RA; Brightling CE
    Lancet Respir Med; 2016 Sep; 4(9):699-707. PubMed ID: 27503237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blinded, double-dummy efficacy and safety study of budesonide-formoterol Spiromax® compared to budesonide-formoterol Turbuhaler® in adults and adolescents with persistent asthma.
    Virchow JC; Rodriguez-Roisin R; Papi A; Shah TP; Gopalan G
    BMC Pulm Med; 2016 Mar; 16():42. PubMed ID: 26987997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety profile of fluticasone furoate administered once daily in the morning or evening: a randomized, double-blind, double-dummy, placebo-controlled trial in adult and adolescent patients with persistent bronchial asthma.
    Medley H; Orozco S; Allen A
    Clin Ther; 2012 Aug; 34(8):1683-95. PubMed ID: 22796247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years.
    Knorr B; Franchi LM; Bisgaard H; Vermeulen JH; LeSouef P; Santanello N; Michele TM; Reiss TF; Nguyen HH; Bratton DL
    Pediatrics; 2001 Sep; 108(3):E48. PubMed ID: 11533366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of tiotropium in children aged 1-5 years with persistent asthmatic symptoms: a randomised, double-blind, placebo-controlled trial.
    Vrijlandt EJLE; El Azzi G; Vandewalker M; Rupp N; Harper T; Graham L; Szefler SJ; Moroni-Zentgraf P; Sharma A; Vulcu SD; Sigmund R; Chawes B; Engel M; Bisgaard H
    Lancet Respir Med; 2018 Feb; 6(2):127-137. PubMed ID: 29361462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial.
    Chupp GL; Bradford ES; Albers FC; Bratton DJ; Wang-Jairaj J; Nelsen LM; Trevor JL; Magnan A; Ten Brinke A
    Lancet Respir Med; 2017 May; 5(5):390-400. PubMed ID: 28395936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.
    FitzGerald JM; Bleecker ER; Nair P; Korn S; Ohta K; Lommatzsch M; Ferguson GT; Busse WW; Barker P; Sproule S; Gilmartin G; Werkström V; Aurivillius M; Goldman M;
    Lancet; 2016 Oct; 388(10056):2128-2141. PubMed ID: 27609406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The CONCEPT trial: a 1-year, multicenter, randomized,double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma.
    FitzGerald JM; Boulet LP; Follows RM
    Clin Ther; 2005 Apr; 27(4):393-406. PubMed ID: 15922813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy and safety of budesonide inhalation suspension: a nebulizable corticosteroid for persistent asthma in infants and young children.
    White MV; Cruz-Rivera M; Walton-Bowen K
    Fam Med; 1999 May; 31(5):337-45. PubMed ID: 10407712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma.
    Chipps BE; Newbold P; Hirsch I; Trudo F; Goldman M
    Ann Allergy Asthma Immunol; 2018 May; 120(5):504-511.e4. PubMed ID: 29409951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase IIa proof-of-concept, placebo-controlled, randomized, double-blind, crossover, single-dose clinical trial of a new class of bronchodilator for acute asthma.
    Swystun V; Green FHY; Dennis JH; Rampakakis E; Lalli G; Fadayomi M; Chiu A; Shrestha G; El Shahat SG; Nelson DE; El Mays TY; Pieron CA; Leigh R
    Trials; 2018 Jun; 19(1):321. PubMed ID: 29914544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.